30 results about "H influenzae type b" patented technology

Peptide-based anti-influenza formulations against influenza A and B are disclosed. The peptides are derived from influenza-based epitopes. The formulations are based on peptide mixtures which may be formulated so that variability is present at particular residues. The formulations can be used to prepare vaccines for preventing influenza in human, avian, murine or equine animals.

Described are kits and methods useful for detection of respiratory pathogens (influenza A (including subtyping capability for H1, H3, H5 and H7 subtypes) influenza B, parainfluenza (type 2), respiratory syncytial virus, and adenovirus) in a sample. Genomic sequence information from the respiratory pathogens was analyzed to identify signature sequences, e.g., polynucleotide sequences useful for confirming the presence or absence of a pathogen in a sample. Primer and probe sets were designed and optimized for use in a PCR based, multiplexed Luminex assay to successfully identify the presence or absence of pathogens in a sample.

The present application describes methods for detecting influenza A and / or influenza B and / or distinguishing between pathogenic and seasonal influenza A subtypes. Many of these preferred formats employ pan-specific antibodies (i.e., that react with all or at least multiple strains within an influenza type) to detect presence of influenza A and / or influenza B and PDZ domains in combination with panspecific antibodies to influenza A to distinguish pathogenic and seasonal influenza A subtypes.

Provided herein are formulations containing copper ions and methods of treating underlying infections and conditions caused by coronavirus, particularly COVID-19, and influenzas, particularly influenza A and / or influenza B using such formulations. Methods of treating the underlying viruses and their resultant conditions using topical copper ion treatments are provided. A topical treatment in its basic form comprises a biocompatible copper ion solution or suspension obtained by leaching of the copper ions from copper metal. The copper ion solution or suspension may be combined with various carriers to form the copper ion treatment including creams or solutions. Methods of making the copper ion solution or suspension from solid copper metal in a biocompatible solution are also provided.

The invention discloses a joint detection kit for novel influenza virus and influenza virus A / B as well as preparation method and application of the joint detection kit. The joint detection kit comprises a detection test strip, the detection test strip comprises a sample pad, a combination pad, a detection pad and an absorption pad which are sequentially connected in an overlapped mode, and the detection pad is provided with a detection line and a quality control line which are parallel to each other; the detection line comprises a first detection line, a second detection line and a third detection line which are separated from one another, the first detection line is coated with a new coronavirus antibody, the second detection line is coated with an influenza A virus antibody, and the third detection line is coated with an influenza B virus antibody. The joint detection kit provided by the invention can simultaneously detect three items of the new coronavirus, the influenza A and the influenza B after one-time sampling treatment, is short in detection time and simple to operate, and avoids missed diagnosis or misdiagnosis in single item detection; besides, the repeated contact between medical staff and patients in multiple sample collection processes is reduced, and the risk of epidemic situation spreading is reduced.

A non-replicating recombinant adeno-associated associated virus (rAAV) having an AAV capsid having packaged therein a vector genome which comprises AAV inverted terminal repeat sequences and at least one nucleic acid sequence encoding four different immunoglobulin regions (a), (b), (c) and (d) is provided. The rAAV-expressed immunoglobulins are useful for providing passive immunization against influenza A and influenza B. Also described herein are compositions containing the rAAV. Methods of vaccinating patients against influenza are provided.

Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.

The present invention provides influenza neuraminidase (NA)-binding human antibodies, which are capable of specifically binding to and neutralizing at least one influenza B virus strain from the B / Victoria lineage and / or at least one influenza B virus strain from the B / Yamagata lineage, as well as antigen-binding fragment thereof. The invention furthermore relates to the use of said antibodies or antigen-binding fragments in the diagnosis, prophylaxis and / or treatment of influenza infection.

The invention discloses a combination of multiple LAMP primers for detecting multiple influenza viruses and its application. The traditional 2 pairs of primers in 6 regions are improved into 4 pairs of primers in 8 regions, F4 and B4 primers are added, and the detection time is shortened , which improves the sensitivity of detection and does not cause false positives between primers. The multiple LAMP primer combination for detecting multiple influenza viruses provided by the present invention can detect whether it is infected with Influenza A H1N1, Influenza A H3N2 or Influenza B, which is efficient and fast, and is conducive to popularization.

The invention provides an application of an astragaloside IV compound or a pharmaceutical composition containing it in the preparation of anti-influenza B virus medicine. Astragaloside IV AST not only has obvious inhibitory effect on the proliferation of influenza B virus in MDCK cells, but also has no cytotoxic effect within the safe concentration range, and has high safety. It is expected to become a clinical anti-influenza B drug with broad application prospects .

The invention provides a one-tube method with multiplex fluorescent PCR detection for human Influenza A and B and new Influenza A H1N1 virus. The method adopts the primers of which the sequence is shown in SEQ ID NO: 1-6, and also adopts the probes of which the sequence is shown in SEQ ID NO: 7-9. The invention also provides a kit for one-tube method with complex fluorescent PCR detection for human Influenza A and B and new Influenza A H1N1 virus. The kit comprises the primers and the probes. The invention adopts InfA / InfB / A (H1N1) specific primers and Taqman probes, and uses FAM / JOE / TAMRA multiplex fluorescein labels to realize the multiplex detection for the human Influenza A and B and new Influenza A H1N1 virus. The invention has the advantages of high specificity, high sensitivity, high speed, simple and convenient operation, low cost and the like, can be used as a multiple-detection reagent for scientific research and clinical application.

Novel models of interactions of the Nonstructural Protein of influenza A and influenza B viruses (NS1A and NS1B, respectively) with dsRNA are presented. On the basis of the models, novel recombinant viruses and vaccines against influenza A and influenza B viruses are provided.

The invention belongs to the field of molecular biological detection. In particular, the invention relates to the detection and typing of influenza viruses. More specifically, the invention relates to the detection and typing of influenza A virus. The invention provides a composition for detecting and typing influenza viruses, application of the composition, a kit comprising the composition and a method for using the composition. By using the composition disclosed by the invention, the influenza A / B does not need to be amplified by a plurality of pairs of primers, the influenza A / B can be simultaneously detected by only one pair of primers, the cost is low, the amplification is more uniform, the whole system is more accurate and stable, and meanwhile, the compatibility of the composition disclosed by the invention with other virus detection systems is better.

Novel antibody pairs for use in an Influenza B diagnostic test.

The invention discloses a buffer solution for cas12a editing DNA as well as a preparation method and application of the buffer solution. The buffer solution is prepared from the following raw materials: 5 to 25 mM of HEPES with the pH of 6.8 to 7.7, 80 to 300 mM of KCl, 5 to 20 mM of MgCl2, 0.5 to 2 percent of glycerol and 0.3 to 0.7 mM of DTT. The preparation method comprises the following steps: preparing an HEPES solution with the required concentration, adjusting the pH value, sequentially adding KCl, MgCl2, glycerol and DTT according to the required concentration, and uniformly mixing to obtain the buffer solution. The HEPES in the invention belongs to a high-purity biological buffering agent, and does not cause degradation and other influences on all reaction components; the buffer solution provided by the invention can increase the sensitivity of cas12a for detecting influenza B DNA by 10-100 times, and the highest sensitivity can reach 100 fM; and the preparation technology is simple, operation is convenient, and high practicability is achieved.

The NS1 protein of influenza virus is a key virulent element with multi-functional roles in virus replication and acts as a strong interferon (IFN) antagonist. A live attenuated virus (LAIV) is provided using a master backbone, which contains the influenza B (HK8038) virus and includes a deletion of the NSI coding region (DelNS1). The LAIV is based on novel adaptive mutations, which support DelNS1 influenza B live attenuated virus (LAIV) replication in vaccine producing cells. DelNS1 influenza B LAIV shows spontaneous cold adaption with preference to grow at 30-33° C. but restriction at 37-39° C. The LAIV can be used to protect a subject, against a lethal challenge of antigenic distant influenza B viruses. DelNS1 LAIV with adaptive mutations for growing in vaccine producing systems is an important strategy for making highly attenuated and immunogenic live attenuated influenza vaccines with the ability to induce broad cross protective immunity for seasonal influenza.

A method for measuring influenza B virus by an immunoassay, which method enables specific detection of influenza B virus with a higher sensitivity than conventional methods, and a device or a kit therefor are disclosed. The method for measuring influenza B virus includes carrying out an immunoassay of influenza B virus by a sandwich method using two kinds of monoclonal antibodies each of which specifically reacts with the region of the 125th to 248th amino acids of matrix protein (M1) of influenza B virus, which two kinds of monoclonal antibodies are capable of binding to the region of the 125th to 248th amino acids of M1 at the same time, or antigen-binding fragments thereof.